Nuo Therapeutics, Inc. (AURX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 5M 10M 15M Q3 '15: 11.8M Q4 '15: 11.5M Q1 '16: 8.1M Q2 '17: 698.9K Q3 '17: 684.4K Q4 '17: 721K Q1 '18: 708.2K Q2 '18: 658K Q3 '18: 756K Q4 '18: 1.4M Q1 '19: 1.2M Q2 '19: 1.2M Q3 '19: 953.3K Q4 '19: 146.2K Q1 '20: 106.9K Q2 '20: 62.8K Q3 '20: 4.9K Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 38.2K Q4 '22: 112.2K Q1 '23: 173.3K Q2 '23: 291.5K Q3 '23: 485.5K Q4 '23: 608.5K Q1 '24: 782K Q2 '24: 1M Q3 '24: 1.2M Q4 '24: 1.4M Q1 '25: 1.6M Q2 '25: 2M Q3 '25: 2.6M Q4 '25: 3.3M Q1 '26: 4.1M Q2 '26: 5.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

-1.5M 0 1.5M 3M 4.5M Q3 '13: 3.6M Q4 '13: 3.1M Q1 '14: 2.5M Q2 '14: 1.8M Q3 '14: 1.7M Q4 '15: 3.5M Q1 '16: 2.2M Q2 '17: -401.8K Q3 '17: -402.7K Q4 '17: -370K Q1 '18: -161.7K Q2 '18: 27.1K Q3 '18: 344.4K Q4 '18: 1.2M Q1 '19: 1.1M Q2 '19: 1M Q3 '19: 825.4K Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 31.8K Q4 '22: 93K Q1 '23: 143.7K Q2 '23: 241.4K Q3 '23: 388.1K Q4 '23: 482.4K Q1 '24: 615.7K Q2 '24: 817.5K Q3 '24: 909.5K Q4 '24: 1.1M Q1 '25: 1.2M Q2 '25: 1.5M Q3 '25: 1.8M Q4 '25: 2.2M Q1 '26: 2.7M Q2 '26: 3.3M Q3 '14 Q4 '17 Q1 '19 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '15: -39.5M Q4 '15: -41.3M Q1 '16: -39.9M Q2 '17: -9.9M Q3 '17: -9.5M Q4 '17: -15.5M Q1 '18: -14.5M Q2 '18: -11.2M Q3 '18: -10.2M Q4 '18: -1.5M Q1 '19: -1.4M Q2 '19: -1.3M Q3 '19: -885.5K Q4 '19: -969.2K Q1 '20: -399.7K Q2 '20: -13.1K Q3 '20: 19.3K Q4 '20: -378.1K Q1 '21: -341.4K Q2 '21: -342.2K Q3 '21: -342.7K Q4 '21: -90.7K Q1 '22: -606.8K Q2 '22: -1.5M Q3 '22: -2.4M Q4 '22: -3.3M Q1 '23: -3.7M Q2 '23: -3.6M Q3 '23: -3.5M Q4 '23: -3.2M Q1 '24: -3M Q2 '24: -2.7M Q3 '24: -2.5M Q4 '24: -2.5M Q1 '25: -2.5M Q2 '25: -2.6M Q3 '25: -2.6M Q4 '25: -2.5M Q1 '26: -2.2M Q2 '26: -1.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-75M -50M -25M 0 25M 50M 75M Q3 '15: -7.7M Q4 '15: -52.8M Q1 '16: -61.8M Q2 '17: -10M Q3 '17: -9.5M Q4 '17: -15M Q1 '18: -14M Q2 '18: -10.6M Q3 '18: -9.9M Q4 '18: -1.5M Q1 '19: -1.6M Q2 '19: -1.4M Q3 '19: -884.4K Q4 '19: -1.2M Q1 '20: -333.6K Q2 '20: 123.8K Q3 '20: 200.9K Q4 '20: 7.7M Q1 '21: 7.5M Q2 '21: 7.5M Q3 '21: 7.5M Q4 '21: -90.7K Q1 '22: -460.3K Q2 '22: -1.4M Q3 '22: -2.3M Q4 '22: -3.2M Q1 '23: -3.7M Q2 '23: -3.6M Q3 '23: -3.5M Q4 '23: -3.2M Q1 '24: -3M Q2 '24: -2.7M Q3 '24: -2.5M Q4 '24: -2.3M Q1 '25: -2.4M Q2 '25: -2.5M Q3 '25: -2.4M Q4 '25: -2.5M Q1 '26: -2.4M Q2 '26: -2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 3.5M 7M 10.5M Q3 '15: 8.9M Q4 '15: 8M Q1 '16: 5.9M Q2 '17: 1.1M Q3 '17: 1.1M Q4 '17: 1.1M Q1 '18: 870K Q2 '18: 630.8K Q3 '18: 411.7K Q4 '18: 163K Q1 '19: 142.7K Q2 '19: 138.1K Q3 '19: 127.9K Q4 '19: 114.6K Q1 '20: 85.9K Q2 '20: 52.3K Q3 '20: 17.6K Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 6.5K Q4 '22: 19.2K Q1 '23: 29.6K Q2 '23: 50.1K Q3 '23: 97.4K Q4 '23: 126.1K Q1 '24: 166.3K Q2 '24: 211.1K Q3 '24: 257.8K Q4 '24: 302.8K Q1 '25: 373.3K Q2 '25: 467.3K Q3 '25: 773.5K Q4 '25: 1.1M Q1 '26: 1.4M Q2 '26: 1.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q3 '15: -15.5M Q4 '15: -14.4M Q1 '16: -13M Q2 '17: -5.8M Q3 '17: -5.1M Q4 '17: -4.9M Q1 '18: -4.2M Q2 '18: -3.4M Q3 '18: -2.5M Q4 '18: -874.4K Q1 '19: -779.4K Q2 '19: -680.1K Q3 '19: -232.8K Q4 '19: -921.7K Q1 '20: -479.1K Q2 '20: -314K Q3 '20: -322.3K Q4 '20: -53.8K Q1 '21: -48.9K Q2 '21: -43.4K Q3 '21: -46.6K Q4 '21: -120K Q1 '22: -853.1K Q2 '22: -2M Q3 '22: -3M Q4 '22: -3.7M Q1 '23: -3.8M Q2 '23: -3.5M Q3 '23: -3.3M Q4 '23: -3.2M Q1 '24: -2.9M Q2 '24: -2.7M Q3 '24: -2.4M Q4 '24: -2.2M Q1 '25: -1.7M Q2 '25: -713.8K Q3 '25: -932.9K Q4 '25: -865K Q1 '26: -1.7M Q2 '26: -2.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q2 '11: -4.5M Q3 '11: -5.2M Q4 '11: -4.3M Q1 '12: -3.8M Q2 '12: -6.9M Q3 '12: -9.5M Q3 '14: -17.3M Q4 '14: -17.9M Q1 '15: -18M Q2 '15: -18.1M Q3 '15: -16M Q4 '15: -15.1M Q1 '16: -13.5M Q3 '21: -46.6K Q4 '21: -120K Q1 '22: -865K Q2 '22: -2M Q3 '22: -3M Q4 '22: -3.8M Q1 '23: -3.8M Q2 '23: -3.5M Q3 '23: -3.3M Q4 '23: -3.2M Q1 '24: -2.9M Q2 '24: -2.7M Q3 '24: -2.6M Q4 '24: -2.4M Q1 '25: -2.1M Q2 '25: -1.1M Q3 '25: -1.2M Q4 '25: -1.1M Q1 '26: -1.7M Q2 '26: -2.4M Q4 '11 Q4 '14 Q1 '16 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '13: 99.1M Q1 '14: 111.2M Q2 '14: 121.6M Q1 '15: 126M Q2 '15: 126M Q1 '16: 126M Q3 '16: 9.9M Q1 '17: 9.9M Q2 '17: 9.9M Q3 '17: 15.9M Q1 '18: 22.7M Q2 '18: 22.9M Q3 '18: 23.7M Q1 '19: 23.7M Q2 '19: 23.7M Q3 '19: 23.7M Q1 '20: 30.5M Q2 '20: 24.2M Q3 '20: 24.2M Q1 '21: 30.3M Q2 '21: 30.3M Q3 '21: 30.3M Q1 '22: 37.1M Q2 '22: 39.8M Q3 '22: 41.1M Q1 '23: 41.8M Q2 '23: 41.8M Q3 '23: 42.1M Q1 '24: 44.2M Q2 '24: 44.7M Q3 '24: 45.6M Q1 '25: 46.8M Q2 '25: 46.8M Q3 '25: 47.5M Q1 '26: 48.3M Q2 '26: 48.4M Q1 '13 Q1 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.20 -0.80 -0.40 0.00 0.40 0.80 1.20 Q3 '15: -0.08 Q4 '15: -0.44 Q1 '16: -0.50 Q2 '17: -1.00 Q3 '17: -0.90 Q4 '17: -1.08 Q1 '18: -0.94 Q2 '18: -0.58 Q3 '18: -0.52 Q4 '18: -0.07 Q1 '19: -0.07 Q2 '19: -0.06 Q3 '19: -0.03 Q4 '19: -0.05 Q1 '20: -0.03 Q2 '20: -0.01 Q3 '20: -0.01 Q4 '20: 0.27 Q1 '21: 0.28 Q2 '21: 0.28 Q3 '21: 0.28 Q4 '21: -0.03 Q1 '22: -0.04 Q2 '22: -0.06 Q3 '22: -0.08 Q4 '22: -0.07 Q1 '23: -0.08 Q2 '23: -0.08 Q3 '23: -0.08 Q4 '23: -0.08 Q1 '24: -0.08 Q2 '24: -0.07 Q3 '24: -0.06 Q4 '24: -0.05 Q1 '25: -0.05 Q2 '25: -0.05 Q3 '25: -0.05 Q4 '25: -0.05 Q1 '26: -0.04 Q2 '26: -0.04 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.